Alana Hippensteele is lead editor at Pharmacy Times®, Contemporary Clinic, and Pharmacy Times Oncology Edition®. She has a master's in Critical Theory and Creative Research from Pacific Northwest College of Art and a bachelor's degree in English and Art History. She has worked as an English instructor at Temple University and held editorial positions at American Cleaning & Hygiene and Tin House.
APhA: Biden $1.9 Trillion COVID-19 Plan is Strong Start to Recovery From Pandemic
January 15th 2021In a statement by the APhA, Scott J. Knoer, executive vice president and CEO of APhA, noted the association’s support for this first step by the Biden administration on the road to recovery from the pandemic.
Read More
Potential Source of Chronic Inflammation in Patients With Obesity May Lead to Treatment
January 6th 2021Chronic, low-level inflammation is one of the main causes of the diseases associated with obesity. For this reason, researchers investigated which cell type was responsible for triggering inflammation in fat tissue.
Read More
The Causes and Characteristics of Congenital Plasminogen Deficiency
December 24th 2020Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses why congenital plasminogen deficiency is often underdiagnosed and describes the causes and characteristics of the disorder.
Read More
Fun Fact: What Did Nursing Mothers Drink for its Medical Properties in the 17th Century?
December 18th 2020Due to the understanding it could support overall health and wellness, this beverage was recommended to nursing mothers and wet nurses in the 17th century in order to pass on its healing properties to infants.
Read More
Understanding the 340B Prime Vendor Program and Supporting Stakeholders During COVID-19
December 15th 2020Under the 340B Prime Vendor Program, the Prime Vendor has several functions that it carries out to support stakeholders in operating and navigate the field so that they can effectively achieve lower 340B drug pricing for those who need it most.
Read More
The Cardiorenal Benefits, Risks of Treating Type 2 Diabetes With SGLT2 Inhibitors
December 11th 2020There are compelling reasons to use sodium-glucose cotransporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes, according to a session at the 2020 ASHP Midyear Clinical Meeting and Exhibition.
Read More
Fun Fact: What Alcohol-infused Drug Was Used to Treat Plague Victims in the 1600s?
December 11th 2020Paracelsus referred to the drug as the “stone of immortality,” which may have been the impetus for his fine-tuning it further. Later, Thomas Sydenham created his own version in the 1600s with the important addition of alcohol.
Read More
Preliminary Results of Ciltacabtagene Autoleucel in Treating Relapsed/Refractory Multiple Myeloma
December 10th 2020Data from a preliminary phase 1b/2 study demonstrated a single low-dose infusion of ciltacabtagene autoleucel resulted in early, deep, and durable responses in heavily pretreated patients with multiple myeloma.
Read More